key: cord-0889218-3n7u4ihg
authors: Weidmann, M. D.; Berry, G. J.; Zucker, J. E.; Huang, S.; Sobieszczyk, M. E.; Green, D. A.
title: Bacterial Pneumonia and Respiratory Culture Utilization among Hospitalized Patients with and without COVID-19 in New York City
date: 2022-02-09
journal: nan
DOI: 10.1101/2022.02.08.22270591
sha: ee7b0c9ab36908fee6c2763eb787874d82fbd664
doc_id: 889218
cord_uid: 3n7u4ihg

COVID-19 is associated with prolonged hospitalization and a high risk of intubation, which raises concern for bacterial co-infection and antimicrobial resistance. Previous research has shown a wide range of bacterial pneumonia rates for COVID-19 patients in a variety of clinical and demographic settings, but none have compared hospitalized COVID-19 patients to patients testing negative for SARS-CoV-2 in similar care settings. We performed a retrospective cohort study on hospitalized patients with COVID-19 testing from 10 March 2020 to 31 December 2020. A total of 19,219 patients were included, of which 3,796 tested positive for SARS-CoV-2. We found a 2.6-fold increase (p < 0.001) in respiratory culture ordering in COVID-19 patients. On a per-patient basis, COVID-19 patients were 1.5-fold more likely than non-COVID patients to have abnormal respiratory cultures (46.8% vs. 30.9%, p <0.001), which was primarily driven by patients requiring intubation. Among patients with pneumonia, a significantly higher proportion of COVID-19 patients had ventilator-associated pneumonia (VAP) relative to non-COVID patients (85.7% vs 55.1%, p <0.001), but a lower proportion had community-acquired (12.2% vs 22.1%, p < 0.01) or hospital-acquired pneumonia (2.1% vs. 22.8%, p < 0.001). There was also a significantly higher proportion of respiratory cultures positive for MRSA, K. pneumoniae, and antibiotic-resistant organisms in COVID-19 patients. Increased rates of respiratory culture ordering for COVID-19 patients therefore appear to be clinically justified for patients requiring intubation, but further research is needed to understand how SARS-CoV-2 increases the risk of VAP.

Concern for bacterial co-infection among COVID-19 patients resulted in empirical antimicrobial 51 therapy given to a large proportion of patients hospitalized at our medical center during 2020 [1] . While a 52 relatively high rate of bacterial and influenza co-infection has characterized hospitalized influenza 53 patients, with estimates ranging from 11% to 35% [2, 3] , less is known about the rate of bacterial 54 pneumonia in hospitalized COVID-19 patients. Further, in influenza, bacterial co-infection has been 55 found to be more frequently of community-origin, with one study of hospitalized adults in the US finding 56 that more than 54% of co-infections in adults were diagnosed within the first 48 hours of hospitalization 57 [3] . Several studies have examined bacterial co-infection for COVID-19 patients in inpatient and ICU 58 settings, generally finding lower rates than for influenza patients [4] [5] [6] [7] . Of the two largest such studies, 59 one found very low rates of community-acquired pneumonia (CAP) (1.5%) [7] , while the other found an 60 overall bacterial pneumonia rate of 2.1%, with the overwhelming majority being HAP or VAP [6, 8] . One 61 study among ICU patients found much higher rates of patients with abnormal respiratory cultures (28%), 62 however 90% of these patients required mechanical ventilation [9] . 63 Therefore, when all hospitalized patients are considered together, rates of bacterial pneumonia 64 appear lower in COVID-19 patients relative to hospitalized influenza patients, and in contrast to 65 influenza, few of these infections are community-acquired. However, none of these studies have assessed 66 the concurrent rate of bacterial co-infections, including HAP and VAP rates, in patients testing negative 67 for SARS-CoV-2 during the same period. This lack of a direct comparison between COVID-19 and non-68 COVID-19 infected patients makes it difficult to determine whether the highly disparate reported rates of 69 bacterial co-infection represent the heterogeneity of the patient populations studied, or a truly elevated 70 risk of bacterial pneumonia associated with SARS-CoV-2 infection. 71

Additionally, respiratory culture utilization among COVID-19 patients has not been previously 72 studied. Understanding the rates of respiratory culture ordering and positivity among COVID-19 patients 73 is needed to determine whether culture ordering is appropriate among hospitalized COVID-19 patients, 74 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.08.22270591 doi: medRxiv preprint of bacterial pneumonia, respiratory culture ordering, bacterial etiologies, and antibiotic resistance between 76 patients testing positive and negative for COVID-19 in the same hospital setting. 77

A retrospective cohort study was conducted on all hospitalized patients with SARS-CoV-2 testing 79 performed at Columbia University Irving Medical Center (CUIMC) located in New York City from 10 80

March 2020 to 31 December 2020. SARS-CoV-2 RT-PCR testing was performed in-house using the 81 following assays: Cobas SARS-CoV-2 (Roche Molecular Systems, Inc., Branchburg, NJ), Xpert Xpress 82 SARS-CoV-2 (Cepheid, Sunnyvale, CA), and a laboratory-developed test from the Wadsworth Center at 83 the New York State Department of Health. 84

Data were extracted from medical records to compare respiratory culture utilization and culture 85 results between COVID-19 and non-COVID patients; these data included time of SARS-CoV-2 testing, 86 SARS-CoV-2 test results, dates of admission and discharge, intubation status, number of respiratory 87 cultures performed, time of respiratory culture orders, and results of respiratory culture testing, including 88 time of culture results, bacterial species recovered, and antimicrobial susceptibility. 89

Rates of respiratory culture utilization and culture positivity were compared between COVID-19 and 90 non-COVID patients, as was the distribution of recovered species, antimicrobial susceptibility profiles, 91 intubation status and ordering time of positive cultures during hospital admission to stratify pneumonia 92 cases into community-acquired (<= 2 days) vs. hospital-acquired (> 2 days) vs ventilator-associated (>2 93 days after intubation) [8] . A positive respiratory culture was defined as any potential respiratory pathogen 94 recovered from culture, whereas a negative result was defined as either no growth, when cultures were 95 resulted as "mixed commensal microbiota," or when only yeast were isolated. Respiratory cultures were 96 excluded if SARS-CoV-2 testing was performed after respiratory cultures were ordered to ensure that all 97 culture results analyzed were from patients of known COVID-19 status at time of testing. 98 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.08.22270591 doi: medRxiv preprint culture ordering, positivity, antibiotic resistance, and CAP, HAP or VAP in COVID-19 positive and 100 negative patients. A two-tailed Student's t-test was used to assess statistical significance in time to 101 respiratory culture positivity (when results of continuous variables were being compared). Data analysis 102 was initially performed using Microsoft Excel, with statistical tests performed using R and R-Studio for 103 reproducibility with scripts included in supplemental data. 104 105

Demographics of SARS-CoV-2 positive and negative populations 107 A total of 19,275 participants were initially included; 3,805 (19.7%) tested positive for SARS-CoV-2 108 and 15,470 (80.3%) tested negative. 56 patients were excluded due to respiratory cultures ordered prior to 109 SARS-CoV-2 testing, leaving 19,219 participants for study analysis. SARS-CoV-2 positivity rates varied 110 widely over the study period, from a peak of nearly 60% in April 2020 to a low of just over 3% in 111

September 2020 (Supplemental Figure 1 ). Demographic characteristics of included patients are 112 shown in Table 1 . Compared to non-COVID patients, COVID-19 patients were older (p < 113 0.001), more likely to be male (p < 0.001), more likely to be Hispanic/Latino, less likely to be 114 white, and were more likely to receive care in the ICU (p < 0.001). The mortality rate was also 115 5.6-fold higher (16.9% vs. 3.0%, p < 0.001) and intubation rate 2.9-fold higher (16.6 vs. 5.7, p < 116 0.001) for COVID-19 patients.

Increased rates of respiratory culture ordering in COVID-19 patients 119 COVID-19 patients were 2.6 times as likely to have respiratory cultures ordered compared to non-120 COVID patients (16.0 % vs 6.2%, p < 0.001, Table 2 ). Although the rate of respiratory culture ordering 121 varied by month ( Figure 1A) , significantly higher ordering was seen among COVID-19 patients across 122 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.08.22270591 doi: medRxiv preprint per patient for COVID-19 patients relative to non-COVID patients (4.3 vs 2.7 per patient, p <0.001, 124

A much higher rate of respiratory culture ordering was seen overall among intubated patients 126 (57.5%) vs non-intubated patients (4.4%). Among intubated patients, however, ordering was still 127 significantly higher for those with COVID-19 compared to non-COVID patients (71.5% vs. 47.4%, p < 128 0.001, Table 2 , Supplementary Figure 2 ). In addition, among patients who did not require intubation, 129 there was also a significantly higher rate of respiratory culture ordering for COVID-19 relative to non-130 COVID patients (6.1 vs 4.1%, p < 0.001, Supplementary Figure Table 3 ). Among patients who had respiratory cultures ordered, COVID-19 patients 135

were also more likely than non-COVID patients to have an abnormal culture (46.8% vs 30.9%, p < 136 0.001). Even accounting for the higher rate of respiratory culture ordering among COVID-19 patients, on 137 a per culture basis, COVID-19 patients still had a higher percentage of positive cultures (33.4% vs 26.9%, 138 p < 0.001, Table 3) . 139

The higher rate of abnormal cultures among COVID-19 patients was primarily driven by patients 140 requiring intubation. A total of 26.7% of all intubated patients had abnormal respiratory cultures collected 141 more than 48 hours after intubation, qualifying as ventilator-associated pneumonia (VAP). Amongst 142 intubated patients, VAP was more than twice as likely in COVID-19 patients relative to non-COVID 143 patients (39.0% vs. 17.9%, p < 0.001, Supplementary Figure 2E , Table 3 ). When looking at only 144 intubated patients who had respiratory cultures ordered, there remained a significantly higher proportion 145 of COVID-19 positive patients with VAP compared to non-COVID patients (62.0% vs. 51.5%, p < 0.01, 146 Table 3 ) However, among non-intubated patients, there were no significant 147 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.08.22270591 doi: medRxiv preprint resulted as abnormal or the proportion of total patients with abnormal respiratory culture results 149 (Supplementary Figure 2E-F, Table 3) . 150

Among culture-positive patients, COVID-19 patients had a significantly lower rate of CAP, defined 151 as abnormal cultures within the first two days of admission, compared to non-COVID patients (12.2% vs 152 22.1%, p < 0.01, Figure 3 , Table 4 ). Conversely a significantly higher proportion of pneumonia cases 153 also occurred at least two days after admission for COVID-19 positive patients relative to non-COVID 154 patients (Figure 3) , and this difference was particularly pronounced in patients with positive cultures at 155 least 10 days after admission (64.8% vs. 42.1%, p < 0.001). When we looked specifically at HAP, defined 156 as abnormal respiratory cultures that resulted more than two days after admission but not in patients who 157 had been ventilated for more than two days, we found a significantly lower rate among COVID-19 158 patients relative to non-COVID patients (2.1% vs. 22.8%, p < 0.001, Figure 3 , Table 4 ). The 159 overwhelming majority (85.7%) of bacterial pneumonia cases among COVID-19 patients were ventilator-160 associated, and this was significantly higher than the rate of VAP in non-COVID patients with bacterial 161 pneumonia (55.1%, p < 0.001, Figure 3 , Table 4 ). Table 1 ). The most common organism overall was P. aeruginosa (Figure 4) . For 166 COVID-19 patients, the most common organisms in descending order were S. aureus, P. aeruginosa and 167 K. pneumonia. For non-COVID patients, the most common organisms in descending order were P. 168 aeruginosa, S. aureus and K. Pneumoniae (Figure 4) . Among patients with abnormal respiratory cultures, 169 methicillin-resistant S. aureus infections (MRSA) were more common for COVID-19 patients (8.9% vs. 170 5.4%, p < 0.05, Figure 4) , and there was a significant increase in the proportion of overall COVID-19 171 positive vs. negative patients with MRSA respiratory infections (1.05% vs. 0.15%, p < 0.001). There was 172 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.08.22270591 doi: medRxiv preprint vs. 16.3%, p < 0.01, Figure 4) . During the first 10 months of the COVID-19 pandemic we found significantly higher utilization of 186 respiratory cultures for COVID-19 patients compared to non-COVID patients at our NYC medical center. 187

Yet despite the increased ordering, intubated COVID-19 patients still had a higher percentage of 188 abnormal respiratory cultures than intubated non-COVID patients, suggesting that COVID-19 patients 189

have an elevated risk for VAP. Bacterial pneumonia in COVID-19 patients was much more likely to be 190 ventilator-associated and less likely to be community acquired when compared to non-COVID patients. 191

When excluding intubated patients, rates of hospital-acquired pneumonia were lower among COVID-19 192 relative to non-COVID patients. This study is the first to directly assess respiratory culture ordering and 193 positivity in COVID-19 and non-COVID patients in the same hospital. Given the higher rate of positivity 194 amongst intubated COVID-19 patients, respiratory culture ordering appears warranted for this subset of 195 hospitalized COVID-19 patients in whom there is a higher suspicion for bacterial pneumonia. 196 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.08.22270591 doi: medRxiv preprint days into hospitalization, and the majority of these occurred well into hospitalization (> 10 days), nearly 198 all these cases qualified as VAP and were therefore attributable to intubation rather than other sources of 199 hospital-acquired infection. Only 0.7% of non-intubated COVID-19 patients were found to have bacterial 200 pneumonia, and when this was normalized to respiratory culture ordering, the rate was lower than that for 201 non-intubated non-COVID patients. We also found similarly low rates of CAP in COVID-19 patients 202 compared to what has previously been cited in the literature. A recent study of hospitalized COVID-19 203

patients looking specifically at rates of bacterial co-infection within the first three days of hospitalization 204 and finding 1.1% with probable infection, and additional 12.4% with possible co-infection, when all types 205 of infection were considered [10] . Looking specifically at respiratory bacterial co-infections, our study 206 found 1.2% of COVID-19 patients with positive cultures in the first three days of hospitalization, in 207 contrast to 6.3% of COVID-19 patients with abnormal cultures representing HAP or VAP by this 208 definition. The low rate of community-acquired respiratory infections we found here further supports 209 these authors' conclusions that empiric antibiotic therapy for COVID-19 patients is generally not 210 indicated during early hospitalization [10, 11] . Similarly, our finding that non-intubated patients had 211 lower rates of bacterial pneumonia, when those rates were normalized by respiratory culture ordering, 212 argues against routine respiratory culture and empiric pneumonia therapy in these patients. However, the 213 relatively high rates of VAP that we found in COVID-19 patients supports a low threshold for respiratory 214 culture ordering and initiation of antimicrobial therapy for intubated patients. 215

Abnormal respiratory cultures of COVID-19 patients were enriched for pathogens associated with 216 hospital-acquired infection with a generally similar proportion non-COVID patients (Figure 4) . However, 217 there were significant increases in both Klebsiella pneumoniae and MRSA respiratory infections, which 218 we interpreted as further corroborating an increased level of hospital-acquired infections for COVID-19 219 positive patients, particularly relative to the total number of patients testing positive. Overall rates of 220 resistance to penicillin-class antibiotics were significantly higher in respiratory isolates from COVID-19 221 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.08.22270591 doi: medRxiv preprint MDR bacterial infections in COVID-19 patients [6, 12] . One such study also showed that there were 223 significant increases in antibiotic resistance by the duration of hospital stay, including rates of MRSA, 224 vancomycin resistant Enterococcus (VRE), ceftriaxone-resistant Enterbacterales, carbapenem-resistant 225

Enterobacterales and carbapenem-resistant P. aeruginosa or A. baumannii [12] . Interestingly, we did not 226 find significant increase in resistance rates between COVID-19 positive and negative patients for 227 ceftriaxone-resistant Enterbacterales, carbapenem-resistant Enterobacterales and carbapenem-resistant P. 228 aeruginosa or A. baumannii. However, further study is necessary to understand the mechanism by which 229

the host environment or indirectly through affecting host exposure to drug resistant pathogens. 231

Some limitations of this study include its representation of data from a single institution only. There 232 were also significant baseline demographic differences in the COVID-19 positive and negative 233 populations. Inadequate SARS-CoV-2 testing capacity also makes results from March of 2020 difficult to 234 interpret, as false negative rates may have been increased in this setting. Prior to March 23 rd , 2020, not all 235

patients admitted to CUIMC were tested for SARS-CoV-2 due to limited capacity, and this population of 236 unknown COVID-19 status was not included in our data. The data available did not include sensitivities 237 for several antibiotic classes, such as fluoroquinolones, aminoglycosides and macrolides, that would have 238 been helpful in a more comprehensive characterization of resistance in our population of patients with 239 bacterial pneumonia. In addition, the data analyzed here represents one period early in the pandemic, 240 during which time rates of COVID-19 varied greatly in the population (Supplemental Figure 1) . The In summary, the data presented here suggests that COVID-19 infection resulted in higher rates of 245 bacterial co-infection relative to patients who tested negative during the same period, but that these 246 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.08.22270591 doi: medRxiv preprint of CAP as seen with other viruses such as influenza. Possible explanations for these findings include 248 longer periods of hospitalization for COVID-19 patients, inadequate infection control practices during 249 acute phases of the pandemic, or direct effects of SARS-CoV-2 itself on the pathogenesis of bacterial 250 pneumonia during intubation. Based on these findings, respiratory culture ordering is indicated for 251 COVID-19 patients with prolonged hospitalization and ventilator dependence. However, further study is 252 necessary to understand why SARS-CoV-2 predisposes intubated patients to VAP. 253 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.08.22270591 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.08.22270591 doi: medRxiv preprint status. D) Percentage of intubated, non-intubated or overall hospitalized patients who have respiratory 320 cultures ordered by COVID-19 status. E) Percent of intubated, non-intubated or overall hospitalized 321 patients with abnormal respiratory culture results out of the total number with cultures ordered by 322 COVID-19 status. For intubated patients, only those respiratory cultures collected more than 48 hours 323 after intubation were included. F) Percent of intubated or overall hospitalized patients with abnormal 324 respiratory cultures out of total patients by COVID-19 status. For intubated patients, only those 325 respiratory cultures collected more than 48 hours after intubation were included. * p < 0.05, ** p < 0.01, 326 *** p < 0. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.08.22270591 doi: medRxiv preprint Figure 1 A B *** ** ** *** *** ns * ** ** *** *** 

Bacteremia and Blood Culture Utilization during COVID-19 Surge in New 256 York City

The frequency of influenza and bacterial coinfection: a systematic review and 258 meta-analysis. Influenza Other Respir Viruses

Bacterial and viral co-infections complicating severe influenza: Incidence and 260 impact among 507 U.S. patients, 2013-14

Bacterial co-infection and secondary infection in patients with COVID-19: a 262 living rapid review and meta-analysis

Co-infections in people with COVID-19: a systematic review and meta-264 analysis

Bacterial and fungal coinfections in COVID-19 patients hospitalized during the 266

New York City pandemic surge

Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in 268

Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study

Management of Adults With Hospital-acquired and Ventilator-associated 271 Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and 272 the

Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia 274 admitted to a French ICU. Ann Intensive Care

Low frequency of community-acquired bacterial co-infection in patients 276 hospitalized for COVID-19 based on clinical, radiological and microbiological criteria: a 277 retrospective cohort study

An observational cohort study of bacterial co-infection and implications for 279 empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West 280

Characterization of Bacterial and Fungal Infections in Hospitalized Patients 282

With Coronavirus Disease 2019 and Factors Associated With Health Care-Associated Infections. 283 Open Forum Infect Dis

 Tables: